Statin Therapy in Stroke Prevention: A Meta-analysis Involving 121,000 Patients

American Journal of Medicine

Volumn 121, Issue 1, 2008, Pages 24-33

  O'Regan, Christopher ^a   Wu, Ping ^a   Arora, Paul ^b   Perri, Dan ^c   Mills, Edward J ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; All cause mortality; Meta analysis; Statins; Stroke

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; AUTHOR; BLEEDING; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DATA ANALYSIS; DATA BASE; DATA EXTRACTION; DRUG EFFECT; HUMAN; INCIDENCE; INFORMATION PROCESSING; LIPOPROTEIN BLOOD LEVEL; META ANALYSIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; SECONDARY PREVENTION; STROKE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; STROKE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 37649022746     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.06.033     Document Type: Article

References (69)

1. American Heart Association. Heart Disease and Stroke Statistics-2006 Update (2006), American Heart Association, Dallas, TX
2. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet 346 (1995) 1647-1653
3. Iso H., Jacobs Jr. D.R., Wentworth D., et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 320 (1989) 904-910
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
5. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 335 (1996) 1001-1009
6. White H.D., Simes R.J., Anderson N.E., et al. Pravastatin therapy and the risk of stroke. N Engl J Med 343 (2000) 317-326
7. Heart Protection Study Collaborative Group. Mrc/bhf heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
8. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
9. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the anglo-scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
10. Collins R., Armitage J., Parish S., et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 363 (2004) 757-767
11. Bucher H.C., Griffith L.E., and Guyatt G.H. Effect of hmgcoa reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med 128 (1998) 89-95
12. Hebert P.R., Gaziano J.M., Chan K.S., and Hennekens C.H. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 278 (1997) 313-321
13. Blauw G.J., Lagaay A.M., Smelt A.H., and Westendorp R.G. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with hmg-coa reductase inhibitors. Stroke 28 (1997) 946-950
14. Briel M., Studer M., Glass T.R., and Bucher H.C. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 117 (2004) 596-606
15. Vaughan C.J., Gotto Jr. A.M., and Basson C.T. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35 (2000) 1-10
16. Briel M., Nordmann A.J., and Bucher H.C. Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and meta-analyses. Curr Opin Lipidol 16 (2005) 601-605
17. Bucher H.C., Griffith L.E., and Guyatt G.H. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 19 (1999) 187-195
18. Studer M., Briel M., Leimenstoll B., et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 165 (2005) 725-730
19. Zhou Z., Rahme E., and Pilote L. Are statins created equal?. Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J 151 (2006) 273-281
20. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
21. NICE. Assessment report: coronary heart disease-statins. Available at: http://www.Nice.Org.Uk/pdf/statins_assessment_report.Pdf 2005. Accessed November 13, 2007.
22. Meade M.O., Guyatt G.H., Cook R.J., et al. Agreement between alternative classifications of acute respiratory distress syndrome. Am J Respir Crit Care Med 163 (2001) 490-493
23. Sheehe P.R. Combination of log relative risk in retrospective studies of disease. Am J Public Health Nations Health 56 (1966) 1745-1750
24. Fleiss J.L. The statistical basis of meta-analysis. Stat Methods Med Res 2 (1993) 121-145
25. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
26. Higgins J.P., and Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002) 1539-1558
27. Thompson S.G., and Higgins J.P. How should meta-regression analyses be undertaken and interpreted?. Stat Med 21 (2002) 1559-1573
28. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Am J Cardiol 72 (1993) 1031-1037
29. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 344 (1994) 633-638
30. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339 (1998) 1349-1357
31. Results of the low-dose (20 mg) pravastatin gissi prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge?. Gissi prevenzione investigators (Gruppo Italiano per lo studio della sopravvivenza nell'infarto miocardico- GISSI). Ital Heart J 1 (2000) 810-820
32. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA 288 (2002) 2998-3007
33. Adams Jr. H.P. Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovasc Dis 5 (1995) 171-177
34. Amarenco P., Bogousslavsky J., Callahan III A., et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006) 549-559
35. Asselbergs F.W., Diercks G.F., Hillege H.L., et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110 (2004) 2809-2816
36. Athyros V.G., Papageorgiou A.A., Mercouris B.R., et al. Treatment with atorvastatin to the national cholesterol educational program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 18 (2002) 220-228
37. Bestehorn H.P., Rensing U.F., Roskamm H., et al. The effect of simvastatin on progression of coronary artery disease. The multicenter coronary intervention study (CIS). Eur Heart J 18 (1997) 226-234
38. Blankenhorn D.H., Azen S.P., Kramsch D.M., et al. Coronary angiographic changes with lovastatin therapy. The monitored atherosclerosis regression study (MARS). Ann Intern Med 119 (1993) 969-976
39. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
40. Crouse III J.R., Byington R.P., Bond M.G., et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-ii). Am J Cardiol 75 (1995) 455-459
41. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
42. Hedblad B., Wikstrand J., Janzon L., et al. Low-dose metoprolol cr/xl and fluvastatin slow progression of carotid intima-media thickness: Main results from the beta-blocker cholesterol-lowering asymptomatic plaque study (BCAPS). Circulation 103 (2001) 721-1726
43. Holdaas H., Fellstrom B., Jardine A.G., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361 (2003) 2024-2031
44. Jukema J.W., Bruschke A.V., van Boven A.J., et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The regression growth evaluation statin study (REGRESS). Circulation 91 (1995) 2528-2540
45. Koren M.J., and Hunninghake D.B. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the Alliance study. J Am Coll Cardiol 44 (2004) 1772-1779
46. Liem A.H., van Boven A.J., Veeger N.J., et al. Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur Heart J 23 (2002) 1931-1937
47. Makuuchi H., Furuse A., Endo M., et al. Effect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgery. Circ J 69 (2005) 636-643
48. Mercuri M., Bond M.G., Sirtori C.R., et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 101 (1996) 627-634
49. Mohler III E.R., Hiatt W.R., and Creager M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108 (2003) 1481-1486
50. Nakagawa T., Kobayashi T., Awata N., et al. Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the prevention of coronary sclerosis (PCS) study. Int J Cardiol 97 (2004) 107-114
51. Nakamura H., Arakawa K., Itakura H., et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial. Lancet 368 (2006) 1155-1163
52. O'Rourke B., Barbir M., Mitchell A.G., et al. Efficacy and safety of fluvastatin therapy for hypercholesterolemia after heart transplantation: results of a randomised double blind placebo controlled study. Int J Cardiol 94 (2004) 235-240
53. Petronio A.S., Amoroso G., Limbruno U., et al. Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: a randomized study with intravascular ultrasound. Am Heart J 149 (2005) 520-526
54. Salonen R., Nyyssonen K., Porkkala E., et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 92 (1995) 1758-1764
55. Serruys P.W., de Feyter P., Macaya C., et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287 (2002) 3215-3222
56. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
57. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention study group. N Engl J Med 333 (1995) 1301-1307
58. Stone P.H., Lloyd-Jones D.M., Kinlay S., et al. Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the vascular basis for the treatment of myocardial ischemia study. Circulation 111 (2005) 1747-1755
59. Teo K.K., Burton J.R., Buller C.E., et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the simvastatin/enalapril coronary atherosclerosis trial (SCAT). Circulation 102 (2000) 1748-1754
60. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
61. Waters D., Higginson L., Gladstone P., et al. Effects of monotherapy with an hmg-coa reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 89 (1994) 959-968
62. Yokoi H., Nobuyoshi M., Mitsudo K., et al. Three-year follow-up results of angiographic intervention trial using an hmg-coa reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study. Circ J 69 (2005) 875-883
63. Zanchetti A., Crepaldi G., Bond M.G., et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS-a randomized double-blind trial. Stroke 35 (2004) 2807-2812
64. Sakamoto T., Kojima S., Ogawa H., et al. Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 97 (2006) 1165-1171
65. Iwashita M., Matsushita Y., Sasaki J., et al. Relation of serum total cholesterol and other factors to risk of cerebral infarction in Japanese men with hypercholesterolemia. Circ J 69 (2005) 1-6
66. Goldstein L.B., Amarenco P., Bogousslavsky J., et al. Statins for secondary stroke prevention in patients without known coronary heart disease: the jury is still out. Cerebrovasc Dis 18 (2004) 1-2
67. Song F., Altman D.G., Glenny A.M., and Deeks J.J. Validity of indirect comparison for estimating efficacy of competing interventions: Empirical evidence from published meta-analyses. BMJ 326 (2003) 472
68. Silva M.A., Swanson A.C., Gandhi P.J., and Tataronis G.R. Statin-related adverse events: a meta-analysis. Clin Ther 28 (2006) 26-35
69. Trubelja N., Vaughan C., and Coplan N.L. The role of statins in preventing stroke. Prev Cardiol 8 (2005) 98-101